CD8A and neoplasm: In syngeneic mouse models, treatment of tumor-bearing mice with dazostinag promoted innate and adaptive immune responses via activation of dendritic cells, NK cells, and CD8+ T cells within the tumor microenvironment (TME) and associated lymphoid tissue, resulting in antitumor responses (1, 2).